Latest news

• J&J gets EU approval for depression nasal spray Spravato

  J&J’s pharma division Janssen says  Spravato (esketamine) is the first antidepressant medicine with a new mechanism of action to reach the European market in more than 30 years. ... Approximately half of all Spravato patients achieved remission at the

• Sage slides off a MOUNTAIN as depression drug flunks trial

  Johnson &Johnson is the first company to score an approval in this category, getting and FDA green light earlier this year for glutamate NMDA receptor modulator  Spravato (esketamine), a nasal spray ... Shortly after Spravato was approved, Allergan’s

• J&J’s ponesimiod tops Aubagio in head-to-head MS trial

  The company does however have a resurgent central nervous system (CNS) therapeutic category following the approval of Spravato(esketamine), a nasal spray for treatment-resistant depression that J&J reckons can

• Stung by critics, J&J says antidepressant Spravato saves money

  Responds to ICER cost effectiveness ruling. Johnson &Johnson insists its nasal spray antidepressant Spravato can reduce the cost of caring for treatment-resistant depression (TRD) compared to oral drugs, in a ... For its part, J&J insists its new cost-per

• Depression drug failure adds to Allergan's woes

  The misfiring of rapastinel is a major blow for the company’s most important late-stage candidate, and is a clear contrast to J&J’s rival treatment Spravato (esketamine), which